As shown in Figure 1 (see also Supplemental Materials, Fig. S1), these HDAC6 inhibitors caused concentration-dependent reductions of neuronal tau aggregates 15 d after compound and AD-tau treatment (DIV22), with activity separated from measures of toxicity (i.e., reduced DAPI-positive nuclei counts or MAP2 dendritic staining). This evidence concerns the gene MAP2 and Alzheimer disease.